Abivax S.A. Stock
Abivax S.A. Stock
A loss of -1.050% shows a downward development for Abivax S.A..
So far the community has only identified positive things for Abivax S.A. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Abivax S.A. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | -1.050% | - | - | - | - | - | - |
| Valneva SE | 1.430% | -12.017% | -4.403% | 90.904% | 77.205% | -43.963% | -40.222% |
| Nanobiotix | 0.330% | 0.814% | 6.511% | 526.445% | 488.995% | 363.636% | 45.226% |
| Transgene S.A. | -5.110% | -19.643% | -31.559% | 27.841% | 31.387% | -48.276% | -46.809% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data